Table 2.
Cancer site | Q1 (low) | Q2 | Q3 | Q4 | Q5 | P trend † |
---|---|---|---|---|---|---|
Prostate | ||||||
No. of cases | 316 | 566 | 795 | 1037 | 1716 | |
HR (95% CI) | 1.00 (Referent) | 1.78 (1.55 to 2.05) | 2.54 (2.23 to 2.89) | 3.34 (2.94 to 3.79) | 5.63 (5.00 to 6.35) | <.001 |
Breast | ||||||
No. of cases | 413 | 639 | 774 | 996 | 1518 | |
HR (95% CI) | 1.00 (Referent) | 1.56 (1.38 to 1.76) | 1.89 (1.68 to 2.13) | 2.45 (2.18 to 2.74) | 3.77 (3.39 to 4.21) | <.001 |
Colorectum | ||||||
No. of cases | 257 | 399 | 460 | 554 | 788 | |
HR (95% CI) | 1.00 (Referent) | 1.56 (1.33 to 1.82) | 1.80 (1.54 to 2.10) | 2.16 (1.87 to 2.51) | 3.08 (2.68 to 3.55) | <.001 |
Lung | ||||||
No. of cases | 221 | 266 | 300 | 342 | 379 | |
HR (95% CI) | 1.00 (Referent) | 1.20 (1.01 to 1.44) | 1.36 (1.15 to 1.62) | 1.54 (1.30 to 1.82) | 1.71 (1.45 to 2.02) | <.001 |
Kidney | ||||||
No. of cases | 76 | 100 | 99 | 122 | 148 | |
HR (95% CI) | 1.00 (Referent) | 1.32 (0.98 to 1.77) | 1.30 (0.97 to 1.76) | 1.61 (1.21 to 2.14) | 1.96 (1.48 to 2.58) | <.001 |
Bladder | ||||||
No. of cases | 62 | 89 | 99 | 126 | 137 | |
HR (95% CI) | 1.00 (Referent) | 1.43 (1.03 to 1.97) | 1.6 (1.16 to 2.19) | 2.04 (1.5 to 2.76) | 2.21 (1.64 to 2.99) | <.001 |
Ovary | ||||||
No. of cases | 60 | 55 | 62 | 73 | 108 | |
HR (95% CI) | 1.00 (Referent) | 0.92 (0.64 to 1.32) | 1.03 (0.72 to 1.47) | 1.22 (0.86 to 1.71) | 1.81 (1.32 to 2.48) | <.001 |
Pancreas | ||||||
No. of cases | 42 | 60 | 71 | 119 | 140 | |
HR (95% CI) | 1.00 (Referent) | 1.43 (0.96 to 2.12) | 1.70 (1.16 to 2.48) | 2.84 (2.00 to 4.03) | 3.37 (2.39 to 4.76) | <.001 |
Cutoff points for quintiles were based on the distribution of all study participants. Hazard ratios (HRs) were estimated using Cox regression and adjusted for age, birth cohort, genotyping array, top 10 principal components for ancestry, and sex (for nonsex-specific cancer only). CI = confidence interval; PRS = polygenic risk score.
Two-sided Wald tests were performed with a type I error of 0.05.